ENTITY
Lonza Group AG

Lonza Group AG (LONN VX)

37
Analysis
Health Care • Switzerland
Lonza Group AG produces organic fine chemicals, biocides, active ingredients, and biotechnology products. The Company offers custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing, and agricultural products industries. Lonza operates production sites in Europe, the United States, and China.
more
bullish•SK Bioscience
•25 Feb 2021 07:47

SK Bioscience IPO - Valuation Analysis

We believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share which would represent 129% higher than...

Logo
424 Views
Share
bullish•SK Bioscience
•07 Feb 2021 02:23

SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The...

Logo
593 Views
Share
bullish•Lonza Group AG
•17 Jul 2020 10:48

Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex

Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...

Logo
595 Views
Share
bullish•MSCI ACWI Index
•20 Feb 2020 07:53

Global Equity Strategy: Buy the Dips

Despite recent weakness across global markets, our weight of the evidence approach continues to lead us to the same conclusions as we posited in...

Logo
493 Views
Share
•29 Jan 2020 07:51

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Logo
543 Views
Share
x